

Emerging epigenetic-modulating therapies in lymphoma

David Sermer, Laura Pasqualucci, Hans-Guido Wendel, Ari Melnick and Anas Younes

<https://doi.org/10.1038/s41571-019-0190-8>

Supplementary Table 1. Summary of ongoing clinical trials of HDAC inhibitors

Epigenetic agent	Combination	Lymphoma subtype	Trial design	Clinicaltrials.gov identifier	Year opened
Entinostat	Pembrolizumab	HL, FL	Phase II	NCT03179930	2017
Vorinostat	Pembrolizumab	HL, FL, DLBCL	Phase I	NCT03150329	2017
CUDC-907	none	DLBCL	Phase II	NCT02674750	2016
CUDC-907	none	Paediatric lymphomas	Phase I	NCT02909777	2016
Resminostat	none	MF	Phase II	NCT02953301	2016
Vorinostat	Lenalidomide+HDT/ASCT	Non-GCB DLBCL	Phase I	NCT02589145	2015
ACY-1215	none	NHL	Phase Ib/II	NCT02091063	2014
Belinostat	Carfilzomib	NHL	Phase I	NCT02142530	2014
Romidepsin	Radiation + Poly ICLC	CTCL	Phase I	NCT02061449	2014
Romidepsin	GemOX-dex	Aggressive NHL	Phase I	NCT02181218	2014
Romidepsin	Doxil	CTCL	Phase I	NCT01902225	2013
Romidepsin	Alisertib	NHL	Phase I	NCT01897012	2013
Romidepsin	GDP	DLBCL, PTCL	Phase I	NCT01846390	2013
Belinostat	Yttrium Y-90	NHL	Phase II	NCT01686165	2012
Vorinostat	R-EPOCH	HIV-related aggressive NHL	Phase I/II	NCT01193842	2010
Vorinostat	Bortezomib	DLBCL, MCL	Phase II	NCT00703664	2008

HL, Hodgkin lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; MF, mycosis fungoides; HDT/ASCT, high-dose chemotherapy/autologous stem cell transplant; GCB, germinal center B-cell; NHL, non-Hodgkin lymphoma; CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma; MCL, mantle cell lymphoma

Supplementary Table 2. Summary of ongoing clinical trials of PRMT5 and IDH inhibitors

Epigenetic agent	Class	Lymphoma subtype	Trial design	Clinicaltrials.gov identifier	Year opened
GSK3326595	PRMT5 inhibitor	NHL	Phase I	NCT02783300	2016
AG-881	IDH1/2 inhibitor	Haematological malignancies	Phase I	NCT02492737	2015
AG-221	IDH2 inhibitor	AITCL	Phase I/II	NCT02273739	2014
AG-120	IDH1 inhibitor	Haematological malignancies	Phase I	NCT02074839	2014
AG-221	IDH2 inhibitor	Haematological malignancies	Phase I/II	NCT01915498	2013

NHL, non-Hodgkin lymphoma; AITL, angioimmunoblastic T-cell lymphoma